AI assistant
DEXCOM INC — Director's Dealing 2021
Sep 14, 2021
30198_dirs_2021-09-13_eedc3864-24b7-419a-b8b5-17c09acb0d5c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2021-09-09
Reporting Person: Murphy Patrick Michael (EVP, Chief Legal Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-09-09 | Common Stock | S | 975 | $541.36 | Disposed | 16266 | Direct |
| 2021-09-09 | Common Stock | S | 12 | $541.76 | Disposed | 16254 | Direct |
Footnotes
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 13,461 unvested restricted stock units, 5,634 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 5,874 of which were granted on March 8, 2020 and shall vest through March 8, 2023, and 1,953 of which were granted on March 8, 2019 and shall vest through March 8, 2022.